Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Johannesburg Stock Exchange  >  Aspen Pharmacare Holdings Limited    APNJ   ZAE000066692

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Aspen and Equity probes halt

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:54am CET

Competition Commission narrows focus to three pharmaceutical firms in its investigation of cancer-drug prices

Writer at Large

The Competition Commission has abandoned its investigation into excessive pricing of certain cancer drugs sold by Aspen Pharmacare and Equity Pharmaceutical because the volumes involved are so low.

In June, the commission announced that it had initiated investigations into a number of pharmaceutical companies & for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in SA& Roche, Genentech and Pfizer were also part of the investigation into excessive pricing. The commission is continuing to investigate complaints against Roche, Genentech and Pfizer.

On Tuesday, the commission said: & Based on the information gathered to date, the commission has decided to drop the investigation against Aspen and Equity because an excessive pricing case cannot be sustained against them.& Sipho Ngwema, head of communications at the commission, disputed the charge that the June announcement was inappropriately rushed.

& We were faced with high prices that we believed had to be investigated in order to get to the facts.

& We discovered at a very early stage [of the investigation] the volumes were too low to even do an excessive pricing investigation,& said Ngwema.

He said instituting an investigation did not assume guilt. & It can also be to absolve a party,& Ngwema said.

Aspen welcomed the decision to drop the investigation. Stephen Saad, group CEO thanked the commissioner, Tembinkosi Bonakele, and the investigating team & for the expeditious and co-operative manner in which the investigation was undertaken& The Aspen share price was not affected by the announcement and was little changed at the close at R304.75 on Wednesday. Alec Abraham, senior analyst at Sasfin Bank, said that the share price did not respond because most investors assumed nothing would come of the investigation.

In June, Aspen issued a statement responding to the commission’s announcement, saying that while it fully acknowledged the vital nature of the cancer drugs being investigated, & these products have a collective turnover of about R3m in the South African private market& The commission’s decision to investigate followed news that in May, the European Commission had launched a Europe-wide investigation into alleged price hiking of critical cancer drugs by Aspen.

At the time, Aspen said it could not comment on the EU Commission’s action, but stressed it was committed to & fair and open competition in markets in the EU and around the world& News of the EU’s move followed investigations in Spain, the UK and Italy.

[email protected]

(c) 2017 Times Media Group. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASPEN PHARMACARE HOLDINGS
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/16 ASPEN PHARMACARE : wants trades audited
01/11 ASPEN PHARMACARE : share price knocked by rumours of investigation target
01/11 ASPEN PHARMACARE : claims manipulation
01/11 ASPEN PHARMACARE : share price knocked by rumours of investigation target
2017 ASPEN PHARMACARE : Ngonyama to head audit committee
2017 ASPEN PHARMACARE : cover story/paradise papers. THE APPLE OF ASPEN'S EYE
2017 ASPEN PHARMACARE : found fit and healthy to finalise AstraZeneca deal
2017 ASPEN PHARMACARE : found fit and healthy to finalise AstraZeneca deal
2017 ASPEN PHARMACARE : completes acquisition of AstraZenecas anaesthetics portfolio
More news
News from SeekingAlpha
2017 Aspen Pharmacare Holdings (APNHY) Investor Presentation - Slideshow
2017 Aspen Pharmacare Has Continued To Grow And Branch Out
2016 Wobbles Aside, Small Pharma Shares Broadly On The Up In 2015
2015 Sector's Smaller Players Show The Way
2015 OPPORTUNITIES AND RISKS IN THE BIOTE : 2 Companies In South Africa
Financials ( ZAR)
Sales 2018 45 685 M
EBIT 2018 11 705 M
Net income 2018 6 780 M
Debt 2018 42 215 M
Yield 2018 1,33%
P/E ratio 2018 16,03
P/E ratio 2019 12,91
EV / Sales 2018 3,49x
EV / Sales 2019 3,21x
Capitalization 117 B
Chart ASPEN PHARMACARE HOLDINGS
Duration : Period :
Aspen Pharmacare Holdings  Technical Analysis Chart | APNJ | ZAE000066692 | 4-Traders
Technical analysis trends ASPEN PHARMACARE HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 326  ZAR
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Stephen Bradley Saad Group Chief Executive Officer & Executive Director
Douglas Dlamini Chairman
Lorraine Hill Group Operating Officer
Sean Capazorio Group Finance Officer
Michael Guy Attridge Executive Director & Group Deputy CEO
Sector and Competitors